newsfilter
← Latest News
PR Newswire·

Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results

  • Soligenix, Inc. announced financial results & updates for the quarter ended September 30, 2026.
  • The company reported zero revenue for the quarter ended September 30, 2026, matching the prior year period.
  • Net loss for the quarter was $1.1 million, or $0.05 per share, compared to $2.5 million in the same 2025 period.
  • Research & development expenses decreased to $0.4 million from $1.6 million due to the termination of the FLASH2 trial & HyBryte™ activities.
  • General & administrative expenses remained flat at $1.0 million for the quarter.
  • Cash & cash equivalents stood at approximately $9.0 million as of September 30, 2026, sufficient to fund operations into Q2 2028.
  • SGX945 (dusquetide) for Behçet's disease showed encouraging biological activity & was well-tolerated in a Phase 2a study.
  • The company is evaluating strategic options including partnerships, licensing, mergers, acquisitions, & government contracts to maximize stockholder value.
  • Maintaining the Nasdaq listing is a priority to ensure access to public capital markets & attract potential partners.
  • The company's Specialized BioTherapeutics segment focuses on SGX302 for psoriasis & SGX942 for oral mucositis.
  • The Public Health Solutions segment includes RiVax® & filovirus vaccine programs supported by government funding & utilizing the ThermoVax® platform.
Company
SOLIGENIX, INC.
Keywords
SOLIGENIX, INC.